Search results
Showing 166 to 180 of 215 results for arthritis
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)
This guidance has been replaced by NICE technology appraisal guidance 199.
NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement
QuikRead go for C-reactive protein testing in primary care (MIB78)
NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care
Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)
This advice has been replaced by NICE HealthTech guidance 521.
Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
The PediGuard for placing pedicle screws in spinal surgery (MIB26)
NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)
We have moved Diagnostics guidance 36 to become HealthTech guidance 521. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.
The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)
This appraisal has been updated and replaced by NICE guideline CG79.
Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)
This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.